Jazz Pharmaceuticals (NASDAQ:JAZZ) Issues Earnings Results

Key Points

• Jazz Pharmaceuticals beat quarterly expectations, reporting adjusted EPS of ($3.88) versus the $4.05 consensus estimate and revenue of $1.24 billion versus $1.21 billion expected. Record third-quarter revenue rose 10% year over year, prompting the company to raise 2026 revenue guidance to $4.775 billion–$4.85 billion.
• Ziihera delivered a strong launch, generating $21 million in third-quarter sales and leading Jazz to raise its estimated peak-sales potential to $3 billion–$5 billion. Xywav sales also increased 12% to $483 million, with management reporting limited impact from high-sodium oxybate generics.
• Key risks include rising competition and a stock decline. Jazz expects potential competitive pressure on Zepzelca from Amgen’s IMDELLTRA in 2027, while shares fell 0.7% to $214.44 despite analysts maintaining a “Moderate Buy” consensus and an average price target of $292.05.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) released its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.05) by $0.17, FiscalAI reports. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%. The company had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion.

Here are the key takeaways from Jazz Pharmaceuticals' conference call:

• Positive Sentiment: Jazz reported record third-quarter revenue of $1.24 billion, up 10% year over year, and raised 2026 revenue guidance to $4.775 billion–$4.85 billion. The company cited broad commercial execution across sleep, oncology and international markets while keeping operating-expense guidance unchanged.
• Positive Sentiment: Ziihera’s launch in first-line HER2-positive metastatic gastroesophageal adenocarcinoma generated $21 million in third-quarter sales and showed strong early community adoption, including a threefold increase in new ordering accounts in September. Jazz estimates a 3,000–4,000-patient annual U.S. addressable population and increased Ziihera’s peak-sales potential to $3 billion–$5 billion.
• Positive Sentiment: Xywav sales rose 12% to $483 million, with approximately 425 net patient additions during the quarter. Management said high-sodium oxybate generics have had limited impact so far and expects Xywav’s low-sodium profile and clinical differentiation to support continued durability into 2027.
• Positive Sentiment: Jazz completed its $820 million acquisition of Actio Biosciences, adding ABS-1230, a precision epilepsy therapy targeting KCNT1 mutations. Initial patient efficacy data are expected this quarter, while the company also advanced its orexin-2 agonist JZP269 into a Phase I trial.
• Negative Sentiment: Zepzelca faces a likely competitive headwind in 2027 from Amgen’s IMDELLTRA following strong first-line maintenance small-cell lung cancer data, although management expects no impact to 2026 guidance. Modeyso revenue growth may also proceed at a more measured pace as Jazz expands from academic centers into community oncology ahead of the ACTION trial readout in the first half of 2027.

Jazz Pharmaceuticals Trading Down 0.7%

Shares of Jazz Pharmaceuticals stock traded down $1.54 on Monday, reaching $214.44. 1,042,884 shares of the company were exchanged, compared to its average volume of 931,315. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The firm has a market capitalization of $13.92 billion, a price-to-earnings ratio of 14.79, a price-to-earnings-growth ratio of 0.43 and a beta of 0.38. The stock has a fifty day moving average price of $231.96 and a 200-day moving average price of $216.24.

Insider Activity

In other Jazz Pharmaceuticals news, CEO Renée Galá sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $236.40, for a total transaction of $472,800.00. Following the transaction, the chief executive officer directly owned 141,394 shares in the company, valued at approximately $33,425,541.60. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena Patil sold 1,200 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the transaction, the executive vice president owned 47,671 shares in the company, valued at $11,485,850.74. This represents a 2.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 94,121 shares of company stock worth $23,337,922. Company insiders own 4.10% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JAZZ. Barclays lifted their price objective on shares of Jazz Pharmaceuticals from $270.00 to $271.00 and gave the company an "overweight" rating in a research note on Thursday, September 10th. Royal Bank Of Canada lowered their target price on shares of Jazz Pharmaceuticals from $299.00 to $296.00 and set an "outperform" rating on the stock in a research note on Thursday, October 8th. UBS Group raised their target price on shares of Jazz Pharmaceuticals from $315.00 to $337.00 and gave the company a "buy" rating in a research note on Friday, September 11th. TD Cowen boosted their price target on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, August 4th. Finally, Needham & Company LLC upped their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $292.05.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.